Revelation Biosciences announces 1-for-30 reverse split, effective Jan 25

Revelation Biosciences announced that, on January 25, the Company will implement a 1-for-30 reverse split of its common stock following approval at its Special Meeting of Stockholders held on January 17, 2024. The reverse stock split will be effective as of the morning of January 25, 2024, and the Company’s common stock will trade on a post-split basis at the beginning of trading on the same date under the existing trading symbol “REVB.” The CUSIP number for the common stock following the reverse stock split will be 76135L507. The reverse stock split is intended to increase the market price per share of the Company’s common stock to regain compliance with the minimum bid continued listing requirement of The Nasdaq Capital Market. Proportionate adjustments will be made to the conversion and exercise prices of the company’s warrants, restricted stock unit awards, stock options and to the number of shares issued and issuable under the Company’s equity incentive plans.